Ventilator-associated pneumonia

J Chastre, JY Fagon - American journal of respiratory and critical …, 2002 - atsjournals.org
Ventilator-associated pneumonia (VAP) continues to complicate the course of 8 to 28% of
patients receiving mechanical ventilation (MV). In contrast to infections of more frequently …

Treatment of community-acquired lower respiratory tract infections in adults

Å Örtqvist - European Respiratory Journal, 2002 - Eur Respiratory Soc
Community-acquired lower respiratory tract infection (LRTI) is a common cause of acute
illness in adults. The spectrum of disease ranges from a mild mucosal colonisation or …

Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia in Latin America: frequency of occurrence and antimicrobial susceptibility …

AC Gales, RN Jones - Diagnostic microbiology and infectious disease, 2002 - Elsevier
In spite of the recent medical advances, lower respiratory tract infections are still the most
frequent infectious causes of mortality worldwide. The objective of this study was to …

Microbiology of newer fluoroquinolones: focus on respiratory pathogens

RN Jones - Diagnostic microbiology and infectious disease, 2002 - Elsevier
Community-acquired pneumonia, acute exacerbations of chronic bronchitis, and acute
sinusitis are among the most common bacterial infections encountered in clinical practice …

Antimicrobial resistance trends in community-acquired respiratory tract pathogens in the Western Pacific Region and South Africa: report from the SENTRY …

JM Bell, JD Turnidge, RN Jones… - International journal of …, 2002 - Elsevier
From 1998 to 1999, a large number of community-acquired respiratory tract isolates of
Streptococcus pneumoniae (n= 566), Haemophilus influenzae (n= 513) and Moraxella …

The macrolides

GT Hansen, KL Metzler, E DeCarolis… - Expert Opinion on …, 2002 - Taylor & Francis
Erythromycin, which was introduced over 50 years ago, was the first macrolide to be used
clinically.“New” macrolides, for the treatment of patients with various infectious diseases …

In vitro activity of linezolid, synercid and telithromcin against genetically defined high level fluoroquinolone-resistant methicillin-resistant Staphylococcus aureus

JLM Bellido, MNG Zufiaurre, FJS Hernandez… - International Journal of …, 2002 - Elsevier
The in vitro activity of levofloxacin, moxifloxacin, gatifloxacin, erythromycin, telithromycin,
linezolid, synercid and vancomycin was measured against 36 genetically defined, gyrA/grlA …

Quinupristin/dalfopristin

SE Sanche, JM Blondeau - Expert Opinion on Pharmacotherapy, 2002 - Taylor & Francis
Gram-positive pathogens are associated with both community-and hospital-acquired
infections. These infections may be life-threatening in hospitalised patients, especially in …

Activité in vitro en 1999/2000 de la levofloxacine vis-à-vis de streptococcus pneumoniae et des streptocoques isolés à l'hôpital et en pratique de ville en France

CJ Soussy, P Weber, R Leclercq, N Moniot-Ville… - Médecine et maladies …, 2002 - Elsevier
Résumé Objectif: Apprécier l'activité de la levofloxacine sur les streptocoques et
pneumocoques Méthode: Mille deux cent cinquante cinq souches de pneumocoques (1015) …